- Home
- ENLT vs ANIP Comparison
ENLT vs ANIP Comparison
Compare ENLT & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- ANIP
- Stock Information
- Founded
- ENLT 2008
- ANIP 2001
- Country
- ENLT Israel
- ANIP United States
- Employees
- ENLT N/A
- ANIP N/A
- Industry
- ENLT
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- ENLT
- ANIP Health Care
- Exchange
- ENLT Nasdaq
- ANIP Nasdaq
- Market Cap
- ENLT 2.0B
- ANIP 1.3B
- IPO Year
- ENLT 2023
- ANIP N/A
- Fundamental
- Price
- ENLT $19.50
- ANIP $58.72
- Analyst Decision
- ENLT Buy
- ANIP Strong Buy
- Analyst Count
- ENLT 3
- ANIP 8
- Target Price
- ENLT $19.67
- ANIP $80.13
- AVG Volume (30 Days)
- ENLT 28.0K
- ANIP 435.3K
- Earning Date
- ENLT 05-06-2025
- ANIP 05-09-2025
- Dividend Yield
- ENLT N/A
- ANIP N/A
- EPS Growth
- ENLT 90.47
- ANIP N/A
- EPS
- ENLT 0.98
- ANIP N/A
- Revenue
- ENLT $397,296,000.00
- ANIP $674,068,000.00
- Revenue This Year
- ENLT $355.90
- ANIP $29.87
- Revenue Next Year
- ENLT $42.83
- ANIP $7.53
- P/E Ratio
- ENLT $19.18
- ANIP N/A
- Revenue Growth
- ENLT 44.42
- ANIP 30.27
- 52 Week Low
- ENLT $14.01
- ANIP $52.50
- 52 Week High
- ENLT $20.19
- ANIP $77.00
- Technical
- Relative Strength Index (RSI)
- ENLT 62.94
- ANIP 35.30
- Support Level
- ENLT $16.87
- ANIP $57.33
- Resistance Level
- ENLT $20.19
- ANIP $59.06
- Average True Range (ATR)
- ENLT 0.63
- ANIP 1.93
- MACD
- ENLT 0.05
- ANIP -0.36
- Stochastic Oscillator
- ENLT 79.26
- ANIP 18.39
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.